MARKET

CALA

CALA

Calithera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.360
-0.045
-1.32%
Closed 16:00 09/25 EDT
OPEN
3.370
PREV CLOSE
3.405
HIGH
3.530
LOW
3.340
VOLUME
807.87K
TURNOVER
--
52 WEEK HIGH
8.18
52 WEEK LOW
2.450
MARKET CAP
237.08M
P/E (TTM)
-2.3278
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Calithera initiates mid-stage lung cancer study with telaglenastat in combination of immunotherapy
Calithera Biosciences (CALA) has commenced Phase 2 (KEAPSAKE) trial of the glutaminase inhibitor telaglenastat (CB-839) in combination with pembrolizumab, carboplatin and pemetrexed.The 120-subject study will evaluate the safety and investigator-assessed progression-free survival
Seekingalpha · 3d ago
Calithera launches mid-stage study of telaglenstat in lung cancer
Calithera Biosciences (CALA) has commenced Phase 2 (KEAPSAKE) trial of the glutaminase inhibitor telaglenastat (CB-839) in combination with pembrolizumab, carboplatin and pemetrexed.The 120-subject study will evaluate the safety and investigator-assessed progression-free survival
Seekingalpha · 3d ago
Calithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial Of Telaglenastat In Combination With Chemoimmunotherapy To Treat Aggressive Form Of Lung Cancer
- Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard-of-care treatment in front-line setting amongpatients with non-small cell lung cancer and a
Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard-of-care treatment in front-line setting amongpatients with non-small cell lung cancer and a · 3d ago
SPAQ, EROS, CALA and AXTA among after-hours movers
Gainers: [[BRY]] +13.1%. [[LWAY]] +7.1%. [[CTMX]] +7%. [[SPAQ]] +6.7%. [[CALA]] +4.4%.Losers: [[GDS]] -4.5%. [[GRAF]] -3.4%. [[AXTA]] -3.2%. [[BHLB]] -2.3%. [[EROS]] -2%.
Seekingalpha · 09/11 21:41
2 “Strong Buy” Healthcare Stocks Under $5 With Massive Upside Potential
After a record-breaking August surge, volatility has made its way back to the Street. With COVID-19 continuing to impact the financial landscape and the race to the White House narrowing, the recent market volatility convey the uncertainty hanging in the balance.That’s not to say compelling plays can
TipRanks · 09/11 13:58
Calithera Terminating Partnership, And Other News: The Good, Bad And Ugly Of Biopharma
Calithera signals terminating partnership with Incyte.Lexicon reports dosing in Phase 2 clinical study for LX9211.Mesoblast approved to carry on its Phase 3 COVID-19 trial.
Seekingalpha · 09/09 11:27
Calithera to Participate in Multiple Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the
GlobeNewswire · 09/04 12:00
Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth
Simply Wall St. · 08/18 11:55
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CALA. Analyze the recent business situations of Calithera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CALA stock price target is 11.10 with a high estimate of 20.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 150
Institutional Holdings: 64.92M
% Owned: 92.01%
Shares Outstanding: 70.56M
TypeInstitutionsShares
Increased
50
6.27M
New
45
2.96M
Decreased
15
2.91M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
President/Chief Executive Officer/Co-Founder/Director
Susan Molineaux
Senior Vice President/Chief Compliance Officer/General Counsel
Sumita Ray
Senior Vice President
Christopher Molineaux
Senior Vice President
Eric Sjogren
Vice President - Finance/Secretary
Stephanie Wong
Vice President
Francesco Parlati
Other
Curtis Hecht
Other
Keith Orford
Lead Director/Independent Director
Deepika Pakianathan
Lead Director/Independent Director
Deepa Pakianathan
Independent Director
Sunil Agarwal
Independent Director
Jonathan Drachman
Independent Director
Scott Garland
Independent Director
Jean George
Independent Director
Suzy Jones
Independent Director
Blake Wise
Independent Director
H. Ward Wolff
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CALA
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Calithera Biosciences Inc stock information, including NASDAQ:CALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CALA stock methods without spending real money on the virtual paper trading platform.